Author(s)

Tommy Choy¹, Murray Baron², Janet E. Pope^1,3*

¹Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario, Canada.
²McGill University, Montreal, Canada.
³Department of Medicine, Division of Rheumatology, St. Joseph’s Health Care, London, Ontario, Canada.

Objective: To determine the efficacy of immunesuppressive treatment over 1 year in early diffuse cutaneous systemic sclerosis (dcSSc). Methods: dcSSc patients with less than 3 years disease duration and at least one year of data enrolled in the CSRG database were included. Regression analyses for achieving at least minimal important differences (MID) for 5 outcomes over one year were done to determine baseline predictors of change and if immunesuppressive treatment yielded the attainment of the MID. Results: 124 patients (mean age 52.3 years; 79.2% female) were included. Variables associated with MID at one year were often the baseline variable and for some outcomes, age, sex, smoking, restrictive lung disease and treatment type. Treatment with immunesuppressive was not found to be associated with achieving MIDs in multivariate analyses. Conclusion: Treatment was associated with achieving a MID change at 1 year using univariate statistics, but not in multivariate models. These observational data do not support improvement with immunesuppressives over one year but there could be confounding or biases comparing with those prescribed immunesuppressives vs. those who don’t.

Immunesuppressive Treatment, Diffuse Cutaneous Systemic Sclerosis

Choy, T. , Baron, M. and Pope, J. (2014) Estimating Benefits from Immunesuppressive Treatment in Diffuse Cutaneous Systemic Sclerosis: Data from the Canadian Scleroderma Research Group. Open Journal of Rheumatology and Autoimmune Diseases, 4, 248-253. doi: 10.4236/ojra.2014.44034.